Special Issue

Nanotechnology Applied in Prevention, Diagnosis and Treatment of Infectious Diseases

Message from the Guest Editor

None of the pandemic in the last two centuries, have been as devastating as COVID-19, which was declared a pandemic by the World Health Organization (WHO) 11 years after the last one. Despite the development of diagnosis, treatment, and vaccines for infectious diseases around the world, overseas movement of people and animals is becoming easier, and the occurrence of emerging, and exotic malignant contagious infectious diseases is increasing due to urban development, environmental destruction, and so on. Artificial nanostructures do not only have physical properties with a high surface area, but also various physicochemical properties (conductivity, catalytic activity, enzyme activity, optical properties, etc.), and they can support vaccines and therapeutic agents. Since the formation of various nanostructures can be used for prevention, diagnosis, and treatment, the convergence of nano- and biotechnology is especially important. Therefore, there is a need to solve the problem of prevention, early diagnosis, and treatment of emerging, newly emerging, exotic malignant contagious infectious diseases with nano- and biotechnology convergence technology.

Guest Editor

Dr. Hvun-Ouk Kim

Department of Biotechnology and Bioengineering, Kangwon National University, Chuncheon 24341, Gangwon-do, Republic of Korea

Deadline for manuscript submissions

closed (20 July 2022)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/78125

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

